Brief: Regulus Completes Phase 1B Trial Of Farabursen For Autosomal Dominant Polycystic Kidney Disease
27/03/2025 11:08
March 27 (Reuters) - Regulus Therapeutics Inc RGLS.O: REGULUS THERAPEUTICS ANNOUNCES SUCCESSFUL COMPLETION OF ITS PHASE 1B MULTIPLE-ASCENDING DOSE (MAD) CLINICAL TRIAL OF FARABURSEN (RGLS8429) FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) REGULUS THERAPEUTICS INC -POSITIVE TOPLINE DATA FROM FOURTH COHORT OF PATIENTS REGULUS THERAPEUTICS-PATIENTS RECEIVING 300 MG FARABURSEN DEMONSTRATED MEAN HALTING OF HEIGHT-ADJUSTED TOTAL KIDNEY VOLUME GROWTH OVER 4 MONTHS REGULUS THERAPEUTICS INC -ON TRACK FOR INITIATION OF PHASE 3 SINGLE PIVOTAL TRIAL IN Q3 2025 Source text: ID:nPnc8pndpa Further company coverage: RGLS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regulus Therapeutics
See all newsBrief: Novartis Completes Acquisition Of Regulus Therapeutics
Brief: Novartis Announces Expiration Of Hart-Scott-Rodino Waiting Period Of Regulus Therapeutics Tender Offer
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics
Regulus Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Regulus Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview